VTAK is the ticker symbol for Catheter Precision, Inc., a publicly traded Healthcare sector company listed on NYSE. 13F Pro tracks VTAK with AI-powered analysis, a 32-signal quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is VTAK a good stock to buy?

VTAK is tracked on 13F Pro with SEC EDGAR data, but is not currently included in our 32-signal AI quality ranking. The full company profile with financials and AI insights is at https://13fpro.ai/company/VTAK.

Where does 13F Pro source VTAK data?

All Catheter Precision, Inc. fundamentals and ownership data come directly from SEC EDGAR. Catheter Precision, Inc. files with the SEC under CIK 1716621. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

Catheter Precision, Inc.(VTAK)— Stock Profile, AI Score & Financials

Healthcare · NYSE · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Catheter Precision, Inc. (VTAK) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. VTAK is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $7.2m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), Catheter Precision, Inc. reports quarterly revenue of $1.0M, net income of $-3.3M, free cash flow of $-2.9M. Top institutional holders of VTAK by reported 13-F value include Virtu Financial, UBS Group AG, GEODE CAPITAL MANAGEMENT, based on the most recent SEC filings. VTAK trades on the NYSE exchange and files with the SEC under CIK 1716621. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VTAK daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Catheter Precision, Inc. directly from SEC EDGAR.

Revenue

$1.0M

Net Income

$-3.3M

Free Cash Flow

$-2.9M

VTAK key financials by period

Catheter Precision, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period	Form	Revenue	Net income	Operating margin
FY 2025	10-K	$819.0K	$-17.2M	—
FY 2024	10-K	$420.0K	$-16.6M	—
FY 2023	10-K	$442.0K	$-70.6M	—
FY 2022	10-K	$14.0K	$-26.9M	—
FY 2021	10-K	$22.0K	$-25.1M	—
FY 2020	10-K	$4.4M	$-36.0M	—

Institutions holding VTAK

Institutional investors reporting a position in Catheter Precision, Inc. on SEC Form 13F.
Institution	Shares	Value	Reported
Virtu Financial	19,861	$17.0K	2026-06-30
UBS Group AG	17,061	$14.5K	2026-06-30
GEODE CAPITAL MANAGEMENT	11,977	$10.2K	2026-06-30
Tower Research Capital (TRC)	9,452	$8.0K	2026-06-30
OSAIC	8,540	$7.3K	2026-06-30
Allworth Financial	300	$255.00	2026-06-30
CITIGROUP	22	$19.00	2026-06-30
Purpose Unlimited	13	$9.00	2026-06-30
HARBOUR INVESTMENTS	8	$7.00	2026-06-30
SBI Securities , Ltd.	5	$4.00	2026-06-30

SEC EDGAR: CIK 1716621 →

Catheter Precision, Inc.

VTAK

NYSESmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $7.2M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.